Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models | Zendy

Max A. Stockslager | Zendy; Seth Malinowski | Zendy; Mehdi Touat | Zendy; Jennifer C. Yoon | Zendy; Jack Geduldig | Zendy; Mahnoor Mirza | Zendy; Annette S. Kim | Zendy; Patrick Y. Wen | Zendy; Kin-Hoe Chow | Zendy; Keith L. Ligon | Zendy; Scott R. Manalis | Zendy

Open Access

Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models

Author(s) -

Max A. Stockslager,

Seth Malinowski,

Mehdi Touat,

Jennifer C. Yoon,

Jack Geduldig,

Mahnoor Mirza,

Annette S. Kim,

Patrick Y. Wen,

Kin-Hoe Chow,

Keith L. Ligon,

Scott R. Manalis

Publication year - 2021

Publication title -

cell reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.264

H-Index - 154

eISSN - 2639-1856

pISSN - 2211-1247

DOI - 10.1016/j.celrep.2021.109788

Subject(s) - temozolomide , biomarker , cancer , ex vivo , neurosphere , oncology , medicine , personalized medicine , in vivo , o 6 methylguanine dna methyltransferase , precision medicine , dna methylation , methyltransferase , cancer research , bioinformatics , computational biology , biology , glioma , methylation , pathology , gene expression , in vitro , genetics , dna , gene , adult stem cell , endothelial stem cell

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research